Cover Page
Cover Page - shares shares in Millions | 3 Months Ended | |
Mar. 29, 2020 | Apr. 24, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 29, 2020 | |
Document Transition Report | false | |
Entity File Number | 001-35406 | |
Entity Registrant Name | Illumina, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 33-0804655 | |
Entity Address, Address Line One | 5200 Illumina Way | |
Entity Address, City or Town | San Diego | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 92122 | |
City Area Code | 858 | |
Local Phone Number | 202-4500 | |
Title of 12(b) Security | Common Stock, $0.01 par value | |
Trading Symbol | ILMN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 147 | |
Entity Central Index Key | 0001110803 | |
Current Fiscal Year End Date | --01-03 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 1,991 | $ 2,042 |
Short-term investments | 1,341 | 1,372 |
Accounts receivable, net | 472 | 573 |
Inventory | 384 | 359 |
Prepaid expenses and other current assets | 136 | 105 |
Total current assets | 4,324 | 4,451 |
Property and equipment, net | 890 | 889 |
Operating lease right-of-use assets | 559 | 555 |
Goodwill | 824 | 824 |
Intangible assets, net | 138 | 145 |
Deferred tax assets, net | 91 | 64 |
Other assets | 435 | 388 |
Total assets | 7,261 | 7,316 |
Current liabilities: | ||
Accounts payable | 130 | 149 |
Accrued liabilities | 425 | 516 |
Long-term debt, current portion | 499 | 0 |
Total current liabilities | 1,054 | 665 |
Operating lease liabilities | 696 | 695 |
Long-term debt | 652 | 1,141 |
Other long-term liabilities | 224 | 202 |
Stockholders’ equity: | ||
Common stock | 2 | 2 |
Additional paid-in capital | 3,631 | 3,560 |
Accumulated other comprehensive income | 6 | 5 |
Retained earnings | 4,240 | 4,067 |
Treasury stock, at cost | (3,244) | (3,021) |
Total stockholders’ equity | 4,635 | 4,613 |
Total liabilities and stockholders’ equity | $ 7,261 | $ 7,316 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Revenue: | ||
Total revenue | $ 859 | $ 846 |
Cost of revenue: | ||
Amortization of acquired intangible assets | 7 | 9 |
Total cost of revenue | 240 | 262 |
Gross profit | 619 | 584 |
Operating expense: | ||
Research and development | 156 | 169 |
Selling, general and administrative | 274 | 211 |
Total operating expense | 430 | 380 |
Income from operations | 189 | 204 |
Other income (expense): | ||
Interest income | 14 | 23 |
Interest expense | (11) | (15) |
Other (expense) income, net | (14) | 21 |
Total other (expense) income, net | (11) | 29 |
Income before income taxes | 178 | 233 |
Provision for income taxes | 5 | 9 |
Consolidated net income | 173 | 224 |
Add: Net loss attributable to noncontrolling interests | 0 | 9 |
Net income attributable to Illumina stockholders | $ 173 | $ 233 |
Earnings per share attributable to Illumina stockholders: | ||
Basic (in dollars per share) | $ 1.18 | $ 1.58 |
Diluted (in dollars per share) | $ 1.17 | $ 1.57 |
Shares used in computing earnings per share: | ||
Basic (in shares) | 147 | 147 |
Diluted (in shares) | 148 | 149 |
Product revenue | ||
Revenue: | ||
Total revenue | $ 701 | $ 667 |
Cost of revenue: | ||
Cost of revenue | 174 | 182 |
Service and other revenue | ||
Revenue: | ||
Total revenue | 158 | 179 |
Cost of revenue: | ||
Cost of revenue | $ 59 | $ 71 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Statement of Comprehensive Income [Abstract] | ||
Consolidated net income | $ 173 | $ 224 |
Unrealized gain on available-for-sale debt securities, net of deferred tax | 1 | 3 |
Total consolidated comprehensive income | 174 | 227 |
Add: Comprehensive loss attributable to noncontrolling interests | 0 | 9 |
Comprehensive income attributable to Illumina stockholders | $ 174 | $ 236 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive (Loss) Income | Retained Earnings | Treasury Stock | Noncontrolling Interests |
Beginning balance (in shares) at Dec. 30, 2018 | 192 | 45 | |||||
Beginning balance at Dec. 30, 2018 | $ 3,845 | $ 2 | $ 3,290 | $ (1) | $ 3,083 | $ (2,616) | $ 87 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income (loss) | 231 | 233 | (2) | ||||
Unrealized gain on available-for-sale debt securities, net of deferred tax | 3 | 3 | |||||
Issuance of common stock, net of repurchases | (59) | 27 | $ (86) | ||||
Share-based compensation | 51 | 51 | |||||
Cumulative-effect adjustment from adoption of ASU | (18) | (18) | |||||
Vesting of redeemable equity awards | (1) | (1) | |||||
Adjustment to the carrying value of redeemable noncontrolling interests | 18 | 18 | |||||
Ending balance (in shares) at Mar. 31, 2019 | 192 | 45 | |||||
Ending balance at Mar. 31, 2019 | 4,070 | $ 2 | 3,385 | 2 | 3,298 | $ (2,702) | 85 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income (loss) | 295 | 296 | (1) | ||||
Unrealized gain on available-for-sale debt securities, net of deferred tax | 3 | 3 | |||||
Issuance of common stock, net of repurchases (in shares) | 1 | ||||||
Issuance of common stock, net of repurchases | 0 | 3 | $ (3) | ||||
Share-based compensation | 48 | 48 | |||||
Adjustment to the carrying value of redeemable noncontrolling interests | (2) | (2) | |||||
Deconsolidation of Helix | (82) | 2 | (84) | ||||
Ending balance (in shares) at Jun. 30, 2019 | 193 | 45 | |||||
Ending balance at Jun. 30, 2019 | 4,332 | $ 2 | 3,436 | 5 | 3,594 | $ (2,705) | 0 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income (loss) | 234 | 234 | |||||
Issuance of common stock, net of repurchases (in shares) | 1 | ||||||
Issuance of common stock, net of repurchases | (172) | 29 | $ (201) | ||||
Share-based compensation | 45 | 45 | |||||
Ending balance (in shares) at Sep. 29, 2019 | 193 | 46 | |||||
Ending balance at Sep. 29, 2019 | 4,439 | $ 2 | 3,510 | 5 | 3,828 | $ (2,906) | 0 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income (loss) | 239 | 239 | |||||
Issuance of common stock, net of repurchases (in shares) | 1 | 1 | |||||
Issuance of common stock, net of repurchases | (115) | $ (115) | |||||
Share-based compensation | 50 | 50 | |||||
Ending balance (in shares) at Dec. 29, 2019 | 194 | 47 | |||||
Ending balance at Dec. 29, 2019 | 4,613 | $ 2 | 3,560 | 5 | 4,067 | $ (3,021) | 0 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net income (loss) | 173 | 173 | |||||
Unrealized gain on available-for-sale debt securities, net of deferred tax | 1 | 1 | |||||
Issuance of common stock, net of repurchases | (191) | 32 | $ (223) | ||||
Share-based compensation | 39 | 39 | |||||
Ending balance (in shares) at Mar. 29, 2020 | 194 | 47 | |||||
Ending balance at Mar. 29, 2020 | $ 4,635 | $ 2 | $ 3,631 | $ 6 | $ 4,240 | $ (3,244) | $ 0 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities: | ||
Consolidated net income | $ 173 | $ 224 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation expense | 37 | 37 |
Amortization of intangible assets | 7 | 10 |
Share-based compensation expense | 39 | 51 |
Accretion of debt discount | 10 | 14 |
Deferred income taxes | (29) | (11) |
Unrealized gains on marketable equity securities | (3) | (2) |
Gain on deconsolidation of GRAIL | (15) | |
Loss on derivative assets related to terminated acquisition | 95 | |
Other | (2) | (3) |
Changes in operating assets and liabilities: | ||
Accounts receivable | 99 | 56 |
Inventory | (24) | (26) |
Prepaid expenses and other current assets | (14) | 6 |
Operating lease right-of-use assets and liabilities, net | (1) | (1) |
Other assets | (11) | (8) |
Accounts payable | (16) | (47) |
Accrued liabilities | (103) | (70) |
Other long-term liabilities | 24 | (17) |
Net cash provided by operating activities | 281 | 198 |
Cash flows from investing activities: | ||
Maturities of available-for-sale securities | 107 | 1,031 |
Purchases of available-for-sale securities | (256) | (117) |
Sales of available-for-sale securities | 186 | 118 |
Proceeds from the deconsolidation of GRAIL | 15 | |
Cash paid for derivative assets related to terminated acquisition | (132) | |
Purchases of property and equipment | (40) | (56) |
Net purchases of strategic investments | (3) | |
Net cash (used in) provided by investing activities | (135) | 988 |
Cash flows from financing activities: | ||
Payments on financing obligations | (1) | |
Common stock repurchases | (188) | (63) |
Taxes paid related to net share settlement of equity awards | (35) | (23) |
Proceeds from issuance of common stock | 32 | 27 |
Net cash used in financing activities | (191) | (60) |
Effect of exchange rate changes on cash and cash equivalents | (6) | |
Net (decrease) increase in cash and cash equivalents | (51) | 1,126 |
Cash and cash equivalents at beginning of period | 2,042 | 1,144 |
Cash and cash equivalents at end of period | $ 1,991 | $ 2,270 |
Organization and Significant Ac
Organization and Significant Accounting Policies | 3 Months Ended |
Mar. 29, 2020 | |
Accounting Policies [Abstract] | |
Organization and Significant Accounting Policies | 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview We are a provider of sequencing- and array-based solutions, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies . Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended December 29, 2019 , from which the prior year balance sheet information herein was derived. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expense, and related disclosure of contingent assets and liabilities. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. Actual results could differ from those estimates. The unaudited condensed consolidated financial statements include our accounts, our wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Fiscal Year Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to Q1 2020 and Q1 2019 refer to the three months ended March 29, 2020 and March 31, 2019 , respectively, which were both 13 weeks. Significant Accounting Policies During Q1 2020 , there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 29, 2019 , except as described in Recently Adopted Accounting Pronouncements below. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments , which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. We adopted the standard on its effective date in the first quarter of 2020 using a modified retrospective approach. The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. There was no material difference to the condensed consolidated financial statements in Q1 2020 due to the adoption of ASU 2016-13. In accordance with ASU 2016-13, we no longer evaluate whether our available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, we assess whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income (loss). We estimate our allowance for credit losses on our trade receivables as described in our Accounts Receivable policy, below. Accounts Receivable Trade accounts receivable are considered past due based on the contractual payment terms. We reserve specific receivables when collectibility is no longer probable. We also reserve a percentage of our trade receivable balance based on collection history and current economic trends that we expect will impact the level of credit losses over the life of our receivables. These reserves are re-evaluated on a regular basis and adjusted, as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. Earnings per Share Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Up to April 25, 2019, the date of Helix’s deconsolidation, per-share losses of Helix were included in the consolidated basic and diluted earnings per share computations based on our share of Helix’s securities. Potentially dilutive common shares consist of shares issuable under convertible senior notes and equity awards. Convertible senior notes have a dilutive impact when the average market price of our common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares. The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share: In millions Q1 2020 Q1 2019 Weighted average shares outstanding 147 147 Effect of potentially dilutive common shares from: Equity awards 1 1 Convertible senior notes — 1 Weighted average shares used in calculating diluted earnings per share 148 149 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 1 1 Derivatives We are exposed to foreign exchange rate risks in the normal course of business. We enter into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other current assets or accrued liabilities and are not designated as hedging instruments. Changes in the value of the derivatives are recognized in other (expense) income, net , along with the remeasurement gain or loss on the foreign currency denominated assets or liabilities. As of March 29, 2020 , we had foreign exchange forward contracts in place to hedge exposures in the euro, Japanese yen, Australian dollar, Canadian dollar, Singapore dollar, Chinese Yuan Renminbi, and British pound. As of March 29, 2020 and December 29, 2019 , the total notional amounts of outstanding forward contracts in place for foreign currency purchases were $294 million and $252 million , respectively. Warranties We generally provide a one -year warranty on instruments. Additionally, we provide a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. |
(Notes)
(Notes) | 3 Months Ended |
Mar. 29, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | 2. REVENUE Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Revenue by Source Q1 2020 Q1 2019 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 553 $ 67 $ 620 $ 481 $ 75 $ 556 Instruments 79 2 81 105 6 111 Total product revenue 632 69 701 586 81 667 Service and other revenue 128 30 158 113 66 179 Total revenue $ 760 $ 99 $ 859 $ 699 $ 147 $ 846 Revenue by Geographic Area Based on region of destination (in millions) Q1 2020 Q1 2019 Americas $ 477 $ 473 Europe, Middle East, and Africa 221 210 Greater China (1) 84 88 Asia-Pacific 77 75 Total revenue $ 859 $ 846 ____________________________________ (1) Region includes revenue from China, Taiwan, and Hong Kong. Performance Obligations We regularly enter into contracts with multiple performance obligations. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of March 29, 2020 , the aggregate amount of the transaction price allocated to remaining performance obligations was $1,151 million , of which approximately 73% is expected to be converted to revenue in the next twelve months , approximately 12% in the following twelve months , and the remainder thereafter. Contract Liabilities Contract liabilities, which consist of deferred revenue and customer deposits, as of March 29, 2020 and December 29, 2019 were $203 million and $209 million , respectively, of which the short-term portions of $158 million and $167 million , respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in Q1 2020 included $67 million of previously deferred revenue that was included in contract liabilities as of December 29, 2019 |
Investments and Fair Value Meas
Investments and Fair Value Measurements | 3 Months Ended |
Mar. 29, 2020 | |
Fair Value Disclosures [Abstract] | |
Investments and Fair Value Measurements | 3. INVESTMENTS AND FAIR VALUE MEASUREMENTS Debt Securities Our short-term investments are primarily available-for-sale debt securities that consisted of the following: March 29, 2020 December 29, 2019 In millions Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Estimated Fair Value Debt securities in government-sponsored entities $ 21 $ — $ — $ 21 $ 18 $ — $ 18 Corporate debt securities 613 2 (5 ) 610 627 3 630 U.S. Treasury securities 591 10 — 601 616 2 618 Total $ 1,225 $ 12 $ (5 ) $ 1,232 $ 1,261 $ 5 $ 1,266 Realized gains and losses are determined based on the specific-identification method and are reported in interest income. Contractual maturities of available-for-sale debt securities, as of March 29, 2020 , were as follows: In millions Estimated Fair Value Due within one year $ 450 After one but within five years 782 Total $ 1,232 We have the ability, if necessary, to liquidate any of our cash equivalents and short-term investments to meet our liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying condensed consolidated balance sheets. Strategic Investments Marketable Equity Securities As of March 29, 2020 and December 29, 2019 , the fair value of our marketable equity securities, included in short-term investments, totaled $109 million and $106 million , respectively. Total unrealized gains on our marketable equity securities, included in other (expense) income, net , were $3 million in Q1 2020 . Non-Marketable Equity Securities As of March 29, 2020 and December 29, 2019 , the aggregate carrying amounts of our non-marketable equity securities without readily determinable fair values, included in other assets, were $220 million . One of our investments is a VIE for which we have concluded that we are not the primary beneficiary, and therefore, we do not consolidate this VIE in our consolidated financial statements. We have determined our maximum exposure to loss, as a result of our involvement with the VIE, to be the carrying value of our investment, which was $190 million as of March 29, 2020 and December 29, 2019 , recorded in other assets. On April 17, 2020, we made an additional $60 million investment in this VIE. Revenue recognized from transactions with our strategic investees was $13 million and $15 million in Q1 2020 and Q1 2019 , respectively. Venture Funds We invest in two venture capital investment funds (the Funds) with capital commitments of $100 million , callable through April 2026 , and up to $160 million , callable through July 2029 , respectively, of which $51 million and up to $160 million , respectively, remained callable as of March 29, 2020 . Our investments in the Funds are accounted for as equity-method investments. The aggregate carrying amounts of the Funds, included in other assets, were $55 million and $53 million as of March 29, 2020 and December 29, 2019 , respectively. Previously Consolidated Variable Interest Entity Helix Holdings I, LLC In July 2015, we obtained a 50% voting equity ownership interest in Helix. At that time, we determined that we had unilateral power over one of the activities that most significantly impacts the economic performance of Helix through its contractual arrangements and, as a result, we were deemed to be the primary beneficiary of Helix and were required to consolidate Helix. The operations of Helix are included in the accompanying condensed consolidated statements of income for Q1 2019 and up to the date of the deconsolidation, described below. During this period, we absorbed 50% of Helix’s losses. On April 25, 2019, we entered into an agreement to sell our interest in, and relinquish control over, Helix. As part of the agreement, (i) Helix repurchased all of our outstanding equity interests in exchange for a contingent value right with a 7 -year term that entitles us to consideration dependent upon the outcome of Helix’s future financing and/or liquidity events, (ii) we ceased having a controlling financial interest in Helix, including unilateral power over one of the activities that most significantly impacts the economic performance of Helix, (iii) we were relieved of any potential obligation to redeem certain noncontrolling interests, and (iv) we no longer have representation on Helix’s board of directors. As a result, we deconsolidated Helix’s financial statements effective April 25, 2019 and recorded a gain on deconsolidation of $39 million in other (expense) income, net. The gain on deconsolidation included (i) the contingent value right received from Helix recorded at a fair value of approximately $30 million , (ii) the derecognition of the carrying amounts of Helix’s assets and liabilities, and (iii) the derecognition of the noncontrolling interests related to Helix. During Q1 2020 , changes in the fair value of the contingent value right resulted in a $3 million unrealized loss, included in other (expense) income, net . Derivative Assets Related to Terminated Acquisition On November 1, 2018, we entered into an Agreement and Plan of Merger (the Merger Agreement ) to acquire Pacific Biosciences of California, Inc. (PacBio) for an all-cash price of approximately $1.2 billion (or $8.00 per share). On January 2, 2020, we entered into an agreement to terminate the Merger Agreement (the Termination Agreement ). Pursuant to the Termination Agreement, we made a cash payment to PacBio of $98 million on January 2, 2020, which represented the Reverse Termination Fee (as defined in the Merger Agreement). The Reverse Termination Fee is repayable, without interest, to us if PacBio enters into a definitive agreement providing for, or consummates, a Change of Control Transaction by September 30, 2020 (as defined in the Termination Agreement), and such transaction is consummated by the two-year anniversary of the execution of the definitive agreement for such Change of Control Transaction. In addition, we made cash payments to PacBio of $18 million in Q4 2019, pursuant to Amendment No. 1 to the Merger Agreement , and $34 million in Q1 2020, pursuant to the Termination Agreement, collectively referred to as the Continuation Advances. Up to the $52 million of Continuation Advances is repayable without interest to us if, within two years of March 31, 2020, PacBio enters into a Change of Control Transaction or raises at least $100 million in equity or debt financing in a single transaction (with the amount repayable dependent on the amount raised by PacBio). The potential repayments of the Continuation Advances and Reverse Termination Fee meet the definition of derivative assets and are recorded at fair value. The $92 million difference between the $132 million in cash paid during Q1 2020 for the Continuation Advances and Reverse Termination Fee and the $40 million fair value of these derivative assets on the payment dates was recorded as selling, general and administrative expenses. Changes in the fair value of the derivative assets are included in other (expense) income, net, and totaled a $4 million unrealized loss in Q1 2020. Fair Value Measurements The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis: March 29, 2020 December 29, 2019 In millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds (cash equivalents) $ 1,733 $ — $ — $ 1,733 $ 1,732 $ — $ — $ 1,732 Debt securities in government-sponsored entities — 21 — 21 — 18 — 18 Corporate debt securities — 610 — 610 — 630 — 630 U.S. Treasury securities 601 — — 601 618 — — 618 Marketable equity securities 109 — — 109 106 — — 106 Contingent value right — — 26 26 — — 29 29 Derivative assets related to terminated acquisition — — 47 47 — — 10 10 Deferred compensation plan assets — 40 — 40 — 48 — 48 Total assets measured at fair value $ 2,443 $ 671 $ 73 $ 3,187 $ 2,456 $ 696 $ 39 $ 3,191 Liabilities: Deferred compensation plan liability $ — $ 38 $ — $ 38 $ — $ 46 $ — $ 46 |
Debt
Debt | 3 Months Ended |
Mar. 29, 2020 | |
Debt Disclosure [Abstract] | |
Debt | 4. DEBT Summary of debt obligations In millions March 29, December 29, Principal amount of 2023 Notes outstanding $ 750 $ 750 Principal amount of 2021 Notes outstanding 517 517 Unamortized discount of liability component of convertible senior notes (116 ) (126 ) Net carrying amount of liability component of convertible senior notes 1,151 1,141 Less: current portion (499 ) — Long-term debt $ 652 $ 1,141 Carrying value of equity component of convertible senior notes, net of debt issuance costs $ 213 $ 213 Fair value of convertible senior notes outstanding (Level 2) $ 1,361 $ 1,549 Weighted-average remaining amortization period of discount on the liability component of convertible senior notes 3.0 years 3.2 years 0% Convertible Senior Notes due 2023 (2023 Notes) On August 21, 2018, we issued $750 million aggregate principal amount of convertible senior notes due 2023 (2023 Notes). The 2023 Notes mature on August 15, 2023, and the implied estimated effective rate of the liability component of the Notes was 3.7% , assuming no conversion option. The 2023 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on an initial conversion rate, subject to adjustment, of 2.1845 shares of common stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $457.77 per share of common stock), only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price in effect on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2023 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events described in the indenture. Regardless of the foregoing circumstances, the holders may convert their notes on or after May 15, 2023 until August 11, 2023. We may redeem for cash all or any portion of the 2023 Notes, at our option, on or after August 20, 2021 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect (currently $595.10 ) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus any accrued and unpaid special interest to, but excluding, the redemption date. The 2023 Notes were not convertible as of March 29, 2020 and had no dilutive impact during the three months ended March 29, 2020 . If the 2023 Notes were converted as of March 29, 2020 , the if-converted value would not exceed the principal amount. 0.5% Convertible Senior Notes due 2021 (2021 Notes) In June 2014, we issued $517 million aggregate principal amount of 2021 Notes. The 2021 Notes mature on June 15, 2021, and the implied estimated effective rates of the liability component of the Notes was 3.5% , assuming no conversion option. The 2021 Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on an initial conversion rate, subject to adjustment, of 3.9318 shares per $1,000 principal amount of the notes (which represents an initial conversion price of approximately $254.34 per share), only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending September 30, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for 20 or more trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the applicable conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the 5 business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per 2021 Notes for each day of such measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified events described in the indenture for the 2021 Notes. Regardless of the foregoing circumstances, the holders of the 2021 Notes may convert their notes on or after March 15, 2021 until June 11, 2021. The potential dilutive impact of the 2021 Notes has been included in our calculation of diluted earnings per share for Q1 2020 . If the 2021 Notes were converted as of March 29, 2020 , the if-converted value would not exceed the principal amount. The 2021 Notes were not convertible as of March 29, 2020. During Q1 2020, the carrying value of the 2021 Notes was reclassified to short-term as they become convertible within twelve months of the balance sheet date. 0% Convertible Senior Notes due 2019 (2019 Notes) In June 2014, we issued $633 million aggregate principal amount of 2019 Notes, and the implied estimated effective rate of the liability component was 2.9% . The 2019 Notes matured on June 15, 2019, and the excess of the conversion value over the principal amount was paid in 0.4 million |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 29, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | 5. STOCKHOLDERS’ EQUITY As of March 29, 2020 , approximately 4.1 million shares remained available for future grants under the 2015 Stock Plan. Restricted Stock Restricted stock activity was as follows: Restricted Stock Units (RSU) Performance Stock Units (PSU)(1) Weighted-Average Grant Date Fair Value per Share Units in thousands RSU PSU Outstanding at December 29, 2019 1,700 271 $ 271.49 $ 258.66 Awarded 82 55 $ 300.29 $ 348.46 Vested (26 ) — $ 198.43 — Cancelled (70 ) (30 ) $ 260.73 $ 254.81 Outstanding at March 29, 2020 1,686 296 $ 274.46 $ 275.65 ______________________________________ (1) The number of units reflect the estimated number of shares to be issued at the end of the performance period. Stock Options Stock option activity was as follows: Options (in thousands) Weighted-Average Exercise Price Outstanding at December 29, 2019 58 $ 56.65 Exercised (17 ) $ 36.62 Outstanding and exercisable at March 29, 2020 41 $ 64.63 ESPP The price at which common stock is purchased under the Employee Stock Purchase Plan (ESPP) is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During Q1 2020 , approximately 0.1 million shares were issued under the ESPP. As of March 29, 2020 , there were approximately 13.4 million shares available for issuance under the ESPP. Share Repurchases On February 5, 2020, our Board of Directors authorized a new share repurchase program, which supersedes all prior and available repurchase authorizations, to repurchase $750 million of outstanding common stock. The repurchases may be completed under a 10b5-1 plan or at management’s discretion. During Q1 2020 , we repurchased 0.7 million shares for approximately $187 million . Authorizations to repurchase approximately $563 million of our common stock remained available as of March 29, 2020 . Share-based Compensation Share-based compensation expense reported in our condensed consolidated statements of income was as follows: In millions Q1 2020 Q1 2019 Cost of product revenue $ 5 $ 5 Cost of service and other revenue 1 1 Research and development 15 18 Selling, general and administrative 18 27 Share-based compensation expense before taxes 39 51 Related income tax benefits (9 ) (10 ) Share-based compensation expense, net of taxes $ 30 $ 41 The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the ESPP during Q1 2020 were as follows: Employee Stock Purchase Rights Risk-free interest rate 1.46% - 2.56% Expected volatility 30% - 37% Expected term 0.5 - 1.0 year Expected dividends 0 % Weighted-average grant-date fair value per share $ 77.19 As of March 29, 2020 , approximately $458 million of total unrecognized compensation cost related to restricted stock and ESPP shares issued to date was expected to be recognized over a weighted-average period of approximately 2.4 years . |
Supplemental Balance Sheet Deta
Supplemental Balance Sheet Details | 3 Months Ended |
Mar. 29, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Supplemental Balance Sheet Details | 6. SUPPLEMENTAL BALANCE SHEET DETAILS Accounts Receivable In millions March 29, December 29, Trade accounts receivable, gross $ 473 $ 575 Allowance for credit losses (1 ) (2 ) Total accounts receivable, net $ 472 $ 573 Inventory In millions March 29, December 29, Raw materials $ 114 $ 108 Work in process 243 225 Finished goods 27 26 Total inventory $ 384 $ 359 Accrued Liabilities In millions March 29, December 29, Contract liabilities, current portion $ 158 $ 167 Accrued compensation expenses 112 154 Accrued taxes payable 54 86 Operating lease liabilities, current portion 46 45 Other, including warranties (a) 55 64 Total accrued liabilities $ 425 $ 516 (a) Changes in the reserve for product warranties were as follows: In millions Q1 2020 Q1 2019 Balance at beginning of period $ 14 $ 19 Additions charged to cost of product revenue 3 3 Repairs and replacements (5 ) (6 ) Balance at end of period $ 12 $ 16 |
Legal Proceedings
Legal Proceedings | 3 Months Ended |
Mar. 29, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings | 7. LEGAL PROCEEDINGS We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 29, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 8. INCOME TAXES Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income. The effective tax rate in Q1 2020 was 2.5% . In Q1 2020 , the decrease from the U.S. federal statutory tax rate of 21% was primarily attributable to discrete tax benefits related to the derivative assets recorded as a result of the terminated PacBio acquisition , the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom, and tax benefits related to share-based compensation. |
Segment Information
Segment Information | 3 Months Ended |
Mar. 29, 2020 | |
Segment Reporting [Abstract] | |
Segment Information | 9. SEGMENT INFORMATION We have one reportable segment, Core Illumina, as of March 29, 2020, which relates to Illumina’s core operations. Prior to the Helix deconsolidation on April 25, 2019, our reportable segments included both Core Illumina and Helix. See note “ 3. Investments and Fair Value Measurements ” for further details. Core Illumina: Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina includes all of our operations, excluding the results of our previously consolidated VIE, Helix. Helix: Helix was established to enable individuals to explore their genetic information by providing affordable sequencing and database services for consumers through third-party partners, driving the creation of an ecosystem of consumer applications. Core Illumina sells products and provides services to Helix in accordance with contractual agreements between the entities. In millions Q1 2020 Q1 2019 Revenue: Core Illumina $ 859 $ 846 Helix — 1 Elimination of intersegment revenue — (1 ) Consolidated revenue $ 859 $ 846 Income (loss) from operations: Core Illumina $ 189 $ 221 Helix — (18 ) Elimination of intersegment earnings — 1 Consolidated income from operations $ 189 $ 204 |
Organization and Significant _2
Organization and Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 29, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. |
Consolidation | The unaudited condensed consolidated financial statements include our accounts, our wholly-owned subsidiaries, majority-owned or controlled companies, and variable interest entities (VIEs) for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. |
Fiscal Year | Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. |
Recently Adopted Accounting Pronouncements | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments , which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. We adopted the standard on its effective date in the first quarter of 2020 using a modified retrospective approach. The cumulative effect of applying the new credit loss standard was not material and, therefore, did not result in an adjustment to retained earnings. There was no material difference to the condensed consolidated financial statements in Q1 2020 due to the adoption of ASU 2016-13. In accordance with ASU 2016-13, we no longer evaluate whether our available-for-sale debt securities in an unrealized loss position are other than temporarily impaired. Instead, we assess whether such unrealized loss positions are credit-related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive income (loss). We estimate our allowance for credit losses on our trade receivables as described in our Accounts Receivable policy, below. |
Accounts Receivable | Trade accounts receivable are considered past due based on the contractual payment terms. We reserve specific receivables when collectibility is no longer probable. We also reserve a percentage of our trade receivable balance based on collection history and current economic trends that we expect will impact the level of credit losses over the life of our receivables. These reserves are re-evaluated on a regular basis and adjusted, as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. |
Earnings per Share | Basic earnings per share attributable to Illumina stockholders is computed based on the weighted average number of common shares outstanding during the period. Diluted earnings per share attributable to Illumina stockholders is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Up to April 25, 2019, the date of Helix’s deconsolidation, per-share losses of Helix were included in the consolidated basic and diluted earnings per share computations based on our share of Helix’s securities. Potentially dilutive common shares consist of shares issuable under convertible senior notes and equity awards. Convertible senior notes have a dilutive impact when the average market price of our common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares. |
Derivatives | We are exposed to foreign exchange rate risks in the normal course of business. We enter into foreign exchange contracts to manage foreign currency risks related to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. These foreign exchange contracts are carried at fair value in other current assets or accrued liabilities and are not designated as hedging instruments. Changes in the value of the derivatives are recognized in other (expense) income, net , along with the remeasurement gain or loss on the foreign currency denominated assets or liabilities. |
Warranties | We generally provide a one -year warranty on instruments. Additionally, we provide a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. |
Organization and Significant _3
Organization and Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Accounting Policies [Abstract] | |
Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share, Earnings Per Share | The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share: In millions Q1 2020 Q1 2019 Weighted average shares outstanding 147 147 Effect of potentially dilutive common shares from: Equity awards 1 1 Convertible senior notes — 1 Weighted average shares used in calculating diluted earnings per share 148 149 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 1 1 |
Revenue (Tables)
Revenue (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | Revenue by Source Q1 2020 Q1 2019 In millions Sequencing Microarray Total Sequencing Microarray Total Consumables $ 553 $ 67 $ 620 $ 481 $ 75 $ 556 Instruments 79 2 81 105 6 111 Total product revenue 632 69 701 586 81 667 Service and other revenue 128 30 158 113 66 179 Total revenue $ 760 $ 99 $ 859 $ 699 $ 147 $ 846 Revenue by Geographic Area Based on region of destination (in millions) Q1 2020 Q1 2019 Americas $ 477 $ 473 Europe, Middle East, and Africa 221 210 Greater China (1) 84 88 Asia-Pacific 77 75 Total revenue $ 859 $ 846 ____________________________________ (1) Region includes revenue from China, Taiwan, and Hong Kong. |
Investments and Fair Value Me_2
Investments and Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Fair Value Disclosures [Abstract] | |
Summary of Short-term Investments | Our short-term investments are primarily available-for-sale debt securities that consisted of the following: March 29, 2020 December 29, 2019 In millions Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Estimated Fair Value Debt securities in government-sponsored entities $ 21 $ — $ — $ 21 $ 18 $ — $ 18 Corporate debt securities 613 2 (5 ) 610 627 3 630 U.S. Treasury securities 591 10 — 601 616 2 618 Total $ 1,225 $ 12 $ (5 ) $ 1,232 $ 1,261 $ 5 $ 1,266 |
Summary of Contractual Maturities of Available-for-sale Debt Securities | Contractual maturities of available-for-sale debt securities, as of March 29, 2020 , were as follows: In millions Estimated Fair Value Due within one year $ 450 After one but within five years 782 Total $ 1,232 |
Summary of Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis | The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis: March 29, 2020 December 29, 2019 In millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds (cash equivalents) $ 1,733 $ — $ — $ 1,733 $ 1,732 $ — $ — $ 1,732 Debt securities in government-sponsored entities — 21 — 21 — 18 — 18 Corporate debt securities — 610 — 610 — 630 — 630 U.S. Treasury securities 601 — — 601 618 — — 618 Marketable equity securities 109 — — 109 106 — — 106 Contingent value right — — 26 26 — — 29 29 Derivative assets related to terminated acquisition — — 47 47 — — 10 10 Deferred compensation plan assets — 40 — 40 — 48 — 48 Total assets measured at fair value $ 2,443 $ 671 $ 73 $ 3,187 $ 2,456 $ 696 $ 39 $ 3,191 Liabilities: Deferred compensation plan liability $ — $ 38 $ — $ 38 $ — $ 46 $ — $ 46 |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Debt Disclosure [Abstract] | |
Summary of Debt Obligations | In millions March 29, December 29, Principal amount of 2023 Notes outstanding $ 750 $ 750 Principal amount of 2021 Notes outstanding 517 517 Unamortized discount of liability component of convertible senior notes (116 ) (126 ) Net carrying amount of liability component of convertible senior notes 1,151 1,141 Less: current portion (499 ) — Long-term debt $ 652 $ 1,141 Carrying value of equity component of convertible senior notes, net of debt issuance costs $ 213 $ 213 Fair value of convertible senior notes outstanding (Level 2) $ 1,361 $ 1,549 Weighted-average remaining amortization period of discount on the liability component of convertible senior notes 3.0 years 3.2 years |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Equity [Abstract] | |
Summary of Restricted Stock Activity and Related Information, Restricted Stock | Restricted stock activity was as follows: Restricted Stock Units (RSU) Performance Stock Units (PSU)(1) Weighted-Average Grant Date Fair Value per Share Units in thousands RSU PSU Outstanding at December 29, 2019 1,700 271 $ 271.49 $ 258.66 Awarded 82 55 $ 300.29 $ 348.46 Vested (26 ) — $ 198.43 — Cancelled (70 ) (30 ) $ 260.73 $ 254.81 Outstanding at March 29, 2020 1,686 296 $ 274.46 $ 275.65 ______________________________________ (1) The number of units reflect the estimated number of shares to be issued at the end of the performance period. |
Summary of Restricted Stock Activity and Related Information, Performance Units | Restricted stock activity was as follows: Restricted Stock Units (RSU) Performance Stock Units (PSU)(1) Weighted-Average Grant Date Fair Value per Share Units in thousands RSU PSU Outstanding at December 29, 2019 1,700 271 $ 271.49 $ 258.66 Awarded 82 55 $ 300.29 $ 348.46 Vested (26 ) — $ 198.43 — Cancelled (70 ) (30 ) $ 260.73 $ 254.81 Outstanding at March 29, 2020 1,686 296 $ 274.46 $ 275.65 ______________________________________ (1) The number of units reflect the estimated number of shares to be issued at the end of the performance period. |
Summary of Stock Option Activity Under all Stock Option Plans | Stock option activity was as follows: Options (in thousands) Weighted-Average Exercise Price Outstanding at December 29, 2019 58 $ 56.65 Exercised (17 ) $ 36.62 Outstanding and exercisable at March 29, 2020 41 $ 64.63 |
Summary of Share-based Compensation Expense for all Stock Awards | Share-based compensation expense reported in our condensed consolidated statements of income was as follows: In millions Q1 2020 Q1 2019 Cost of product revenue $ 5 $ 5 Cost of service and other revenue 1 1 Research and development 15 18 Selling, general and administrative 18 27 Share-based compensation expense before taxes 39 51 Related income tax benefits (9 ) (10 ) Share-based compensation expense, net of taxes $ 30 $ 41 |
Summary of Assumptions used to Estimate the Weighted-Average Fair Value Per Share for Stock Purchase under the Employee Stock Purchase Plan | The assumptions used for the specified reporting periods and the resulting estimates of weighted-average fair value per share for stock purchased under the ESPP during Q1 2020 were as follows: Employee Stock Purchase Rights Risk-free interest rate 1.46% - 2.56% Expected volatility 30% - 37% Expected term 0.5 - 1.0 year Expected dividends 0 % Weighted-average grant-date fair value per share $ 77.19 |
Supplemental Balance Sheet De_2
Supplemental Balance Sheet Details (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Accounts Receivable | Accounts Receivable In millions March 29, December 29, Trade accounts receivable, gross $ 473 $ 575 Allowance for credit losses (1 ) (2 ) Total accounts receivable, net $ 472 $ 573 |
Summary of Inventory | Inventory In millions March 29, December 29, Raw materials $ 114 $ 108 Work in process 243 225 Finished goods 27 26 Total inventory $ 384 $ 359 |
Summary of Accrued Liabilities | Accrued Liabilities In millions March 29, December 29, Contract liabilities, current portion $ 158 $ 167 Accrued compensation expenses 112 154 Accrued taxes payable 54 86 Operating lease liabilities, current portion 46 45 Other, including warranties (a) 55 64 Total accrued liabilities $ 425 $ 516 |
Summary of Changes in Reserve for Product Warranties | Changes in the reserve for product warranties were as follows: In millions Q1 2020 Q1 2019 Balance at beginning of period $ 14 $ 19 Additions charged to cost of product revenue 3 3 Repairs and replacements (5 ) (6 ) Balance at end of period $ 12 $ 16 |
Segment Information (Tables)
Segment Information (Tables) | 3 Months Ended |
Mar. 29, 2020 | |
Segment Reporting [Abstract] | |
Summary of Operating Performance and Assets by Segment | Core Illumina sells products and provides services to Helix in accordance with contractual agreements between the entities. In millions Q1 2020 Q1 2019 Revenue: Core Illumina $ 859 $ 846 Helix — 1 Elimination of intersegment revenue — (1 ) Consolidated revenue $ 859 $ 846 Income (loss) from operations: Core Illumina $ 189 $ 221 Helix — (18 ) Elimination of intersegment earnings — 1 Consolidated income from operations $ 189 $ 204 |
Organization and Significant _4
Organization and Significant Accounting Policies - Summary of Calculation of Weighted Average Shares used to Calculate Basic and Diluted Earnings Per Share (Details) - shares shares in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Weighted average shares used to calculate basic and diluted earnings per share | ||
Weighted average shares outstanding (in shares) | 147 | 147 |
Effect of potentially dilutive common shares from: | ||
Equity awards (in shares) | 1 | 1 |
Convertible senior notes (in shares) | 0 | 1 |
Weighted average shares used in calculating diluted earnings per share (in shares) | 148 | 149 |
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (in shares) | 1 | 1 |
Organization and Significant _5
Organization and Significant Accounting Policies - Narrative - Derivatives (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Not Designated as Hedging Instrument | Foreign Exchange Forward | ||
Derivative [Line Items] | ||
Derivative, notional amount | $ 294 | $ 252 |
Organization and Significant _6
Organization and Significant Accounting Policies - Narrative - Warranties (Details) | 3 Months Ended |
Mar. 29, 2020 | |
Instruments | |
Product Warranty Liability [Line Items] | |
Warranty period | 1 year |
Minimum | Consumables | |
Product Warranty Liability [Line Items] | |
Warranty period | 6 months |
Maximum | Consumables | |
Product Warranty Liability [Line Items] | |
Warranty period | 12 months |
Revenue - Disaggregation of Rev
Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 859 | $ 846 |
Americas | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 477 | 473 |
Europe, Middle East, and Africa | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 221 | 210 |
Greater China | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 84 | 88 |
Asia-Pacific | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 77 | 75 |
Consumables | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 620 | 556 |
Instruments | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 81 | 111 |
Product revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 701 | 667 |
Service and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 158 | 179 |
Sequencing | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 760 | 699 |
Sequencing | Consumables | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 553 | 481 |
Sequencing | Instruments | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 79 | 105 |
Sequencing | Product revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 632 | 586 |
Sequencing | Service and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 128 | 113 |
Microarray | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 99 | 147 |
Microarray | Consumables | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 67 | 75 |
Microarray | Instruments | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2 | 6 |
Microarray | Product revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 69 | 81 |
Microarray | Service and other revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 30 | $ 66 |
Revenue - Remaining Performance
Revenue - Remaining Performance Obligation (Details) $ in Millions | Mar. 29, 2020USD ($) |
Accounting Policies [Abstract] | |
Remaining performance obligation | $ 1,151 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-30 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Percent of remaining performance obligation | 73.00% |
Expected timing of remaining performance obligation | 12 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-03-30 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Percent of remaining performance obligation | 12.00% |
Expected timing of remaining performance obligation | 12 months |
Revenue - Narrative (Details)
Revenue - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Dec. 29, 2019 | |
Revenue from Contract with Customer [Abstract] | ||
Contract with customer, liability | $ 203 | $ 209 |
Contract liabilities, current portion | 158 | $ 167 |
Revenue recognized | $ 67 |
Investments and Fair Value Me_3
Investments and Fair Value Measurements - Summary of Short-term Investments (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Available-for-sale debt securities: | ||
Amortized Cost | $ 1,225 | $ 1,261 |
Gross Unrealized Gains | 12 | 5 |
Gross Unrealized Losses | (5) | |
Estimated Fair Value | 1,232 | 1,266 |
Debt securities in government-sponsored entities | ||
Available-for-sale debt securities: | ||
Amortized Cost | 21 | 18 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | |
Estimated Fair Value | 21 | 18 |
Corporate debt securities | ||
Available-for-sale debt securities: | ||
Amortized Cost | 613 | 627 |
Gross Unrealized Gains | 2 | 3 |
Gross Unrealized Losses | (5) | |
Estimated Fair Value | 610 | 630 |
U.S. Treasury securities | ||
Available-for-sale debt securities: | ||
Amortized Cost | 591 | 616 |
Gross Unrealized Gains | 10 | 2 |
Gross Unrealized Losses | 0 | |
Estimated Fair Value | $ 601 | $ 618 |
Investments and Fair Value Me_4
Investments and Fair Value Measurements - Summary of Contractual Maturities of Available-for-sale Debt Securities (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Estimated Fair Value | ||
Due within one year | $ 450 | |
After one but within five years | 782 | |
Total | $ 1,232 | $ 1,266 |
Investments and Fair Value Me_5
Investments and Fair Value Measurements - Narrative (Details) | Apr. 17, 2020USD ($) | Jan. 02, 2020USD ($) | Apr. 25, 2019USD ($) | Nov. 01, 2018USD ($)$ / shares | Mar. 02, 2020USD ($) | Mar. 29, 2020USD ($)fund | Dec. 29, 2019USD ($) | Mar. 31, 2019USD ($) | Jul. 31, 2015 |
Schedule of Investments [Line Items] | |||||||||
Marketable equity securities | $ 109,000,000 | $ 106,000,000 | |||||||
Marketable equity securities unrealized losses and gains | 3,000,000 | $ 2,000,000 | |||||||
Strategic equity investments, without readily determinable fair values | 220,000,000 | 220,000,000 | |||||||
Carrying value of investment | $ 190,000,000 | 190,000,000 | |||||||
Number of venture capital investment funds | fund | 2 | ||||||||
Equity method investments | $ 55,000,000 | 53,000,000 | |||||||
Gains on deconsolidation | 15,000,000 | ||||||||
Loss on derivative assets related to terminated acquisition | 95,000,000 | ||||||||
Investee | |||||||||
Schedule of Investments [Line Items] | |||||||||
Revenue from transactions with strategic investees | 13,000,000 | $ 15,000,000 | |||||||
Venture Capital Investment Fund (the Fund) | |||||||||
Schedule of Investments [Line Items] | |||||||||
Commitment in new venture capital investment fund | 100,000,000 | ||||||||
Remaining capital commitment | 51,000,000 | ||||||||
Second Venture Capital Investment Fund | |||||||||
Schedule of Investments [Line Items] | |||||||||
Commitment in new venture capital investment fund | 160,000,000 | ||||||||
Remaining capital commitment | 160,000,000 | ||||||||
Helix Holdings I, LLC | |||||||||
Schedule of Investments [Line Items] | |||||||||
Contingent value right, terms | 7 years | ||||||||
Gains on deconsolidation | $ 39,000,000 | ||||||||
Contingent value right | $ 30,000,000 | ||||||||
Unrealized gain (loss) from contingent value right | $ 3,000,000 | ||||||||
Helix Holdings I, LLC | Variable Interest Entity, Primary Beneficiary | |||||||||
Schedule of Investments [Line Items] | |||||||||
Absorbed Helix's losses percentage | 50.00% | ||||||||
Fair Value, Measurements, Recurring | |||||||||
Schedule of Investments [Line Items] | |||||||||
Marketable equity securities | $ 109,000,000 | 106,000,000 | |||||||
Contingent value right | 26,000,000 | 29,000,000 | |||||||
Derivative asset | 47,000,000 | 10,000,000 | |||||||
Pacific Biosciences of California, Inc (PacBio) | |||||||||
Schedule of Investments [Line Items] | |||||||||
Cash payments to PacBio | $ 1,200,000,000 | $ 34,000,000 | 132,000,000 | $ 18,000,000 | |||||
Share price (in dollars per share) | $ / shares | $ 8 | ||||||||
Termination fee | $ 98,000,000 | ||||||||
Business combination, contingent consideration arrangements, maximum outcome | 52,000,000 | ||||||||
Equity or debt financing to be raised | $ 100,000,000 | ||||||||
Derivative asset | 40,000,000 | ||||||||
Helix Holdings I, LLC | Variable Interest Entity, Primary Beneficiary | |||||||||
Schedule of Investments [Line Items] | |||||||||
Equity ownership interest percentage | 50.00% | ||||||||
Selling, general and administrative | Pacific Biosciences of California, Inc (PacBio) | |||||||||
Schedule of Investments [Line Items] | |||||||||
Loss on derivative assets related to terminated acquisition | 92,000,000 | ||||||||
Other Operating Income (Expense) | Pacific Biosciences of California, Inc (PacBio) | |||||||||
Schedule of Investments [Line Items] | |||||||||
Loss on derivative assets related to terminated acquisition | $ 4,000,000 | ||||||||
Subsequent Event | |||||||||
Schedule of Investments [Line Items] | |||||||||
Payments to acquire additional investment in security | $ 60,000,000 |
Investments and Fair Value Me_6
Investments and Fair Value Measurements - Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Assets: | ||
Available-for-sale securities | $ 1,232 | $ 1,266 |
Marketable equity securities | 109 | 106 |
Debt securities in government-sponsored entities | ||
Assets: | ||
Available-for-sale securities | 21 | 18 |
Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 610 | 630 |
U.S. Treasury securities | ||
Assets: | ||
Available-for-sale securities | 601 | 618 |
Fair Value, Measurements, Recurring | ||
Assets: | ||
Marketable equity securities | 109 | 106 |
Contingent value right | 26 | 29 |
Derivative assets related to terminated acquisition | 47 | 10 |
Deferred compensation plan assets | 40 | 48 |
Total assets measured at fair value | 3,187 | 3,191 |
Liabilities: | ||
Deferred compensation plan liability | 38 | 46 |
Fair Value, Measurements, Recurring | Debt securities in government-sponsored entities | ||
Assets: | ||
Available-for-sale securities | 21 | 18 |
Fair Value, Measurements, Recurring | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 610 | 630 |
Fair Value, Measurements, Recurring | U.S. Treasury securities | ||
Assets: | ||
Available-for-sale securities | 601 | 618 |
Fair Value, Measurements, Recurring | Money market funds (cash equivalents) | ||
Assets: | ||
Money market funds (cash equivalents) | 1,733 | 1,732 |
Fair Value, Measurements, Recurring | Level 1 | ||
Assets: | ||
Marketable equity securities | 109 | 106 |
Contingent value right | 0 | 0 |
Derivative assets related to terminated acquisition | 0 | 0 |
Deferred compensation plan assets | 0 | 0 |
Total assets measured at fair value | 2,443 | 2,456 |
Liabilities: | ||
Deferred compensation plan liability | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Debt securities in government-sponsored entities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | U.S. Treasury securities | ||
Assets: | ||
Available-for-sale securities | 601 | 618 |
Fair Value, Measurements, Recurring | Level 1 | Money market funds (cash equivalents) | ||
Assets: | ||
Money market funds (cash equivalents) | 1,733 | 1,732 |
Fair Value, Measurements, Recurring | Level 2 | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Contingent value right | 0 | 0 |
Derivative assets related to terminated acquisition | 0 | 0 |
Deferred compensation plan assets | 40 | 48 |
Total assets measured at fair value | 671 | 696 |
Liabilities: | ||
Deferred compensation plan liability | 38 | 46 |
Fair Value, Measurements, Recurring | Level 2 | Debt securities in government-sponsored entities | ||
Assets: | ||
Available-for-sale securities | 21 | 18 |
Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 610 | 630 |
Fair Value, Measurements, Recurring | Level 2 | U.S. Treasury securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Money market funds (cash equivalents) | ||
Assets: | ||
Money market funds (cash equivalents) | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Contingent value right | 26 | 29 |
Derivative assets related to terminated acquisition | 47 | 10 |
Deferred compensation plan assets | 0 | 0 |
Total assets measured at fair value | 73 | 39 |
Liabilities: | ||
Deferred compensation plan liability | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Debt securities in government-sponsored entities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | U.S. Treasury securities | ||
Assets: | ||
Available-for-sale securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Money market funds (cash equivalents) | ||
Assets: | ||
Money market funds (cash equivalents) | $ 0 | $ 0 |
Debt - Summary of Debt Obligati
Debt - Summary of Debt Obligations (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 29, 2020 | Dec. 29, 2019 | Aug. 21, 2018 | Jun. 29, 2014 | |
Debt Instrument [Line Items] | ||||
Less: current portion | $ (499,000,000) | $ 0 | ||
Long-term debt | 652,000,000 | 1,141,000,000 | ||
Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Unamortized discount of liability component of convertible senior notes | (116,000,000) | (126,000,000) | ||
Net carrying amount of liability component of convertible senior notes | 1,151,000,000 | 1,141,000,000 | ||
Carrying value of equity component, net of debt issuance cost | $ 213,000,000 | $ 213,000,000 | ||
Weighted-average remaining amortization period of discount on the liability component of convertible senior notes | 3 years | 3 years 2 months 12 days | ||
Level 2 | Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Fair value of convertible senior notes outstanding (Level 2) | $ 1,361,000,000 | $ 1,549,000,000 | ||
2023 | Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount of notes outstanding | 750,000,000 | 750,000,000 | $ 750,000,000 | |
2021 | Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount of notes outstanding | $ 517,000,000 | $ 517,000,000 | $ 517,000,000 |
Debt - Narrative (Details)
Debt - Narrative (Details) - Convertible Senior Notes | Jun. 15, 2019shares | Aug. 21, 2018USD ($)day$ / shares | Jun. 29, 2014USD ($)day$ / shares | Mar. 29, 2020USD ($) | Dec. 29, 2019USD ($) |
2023 | |||||
Debt Instrument [Line Items] | |||||
Stated rate | 0.00% | ||||
Principal amount of notes outstanding | $ | $ 750,000,000 | $ 750,000,000 | $ 750,000,000 | ||
Effective interest rate used to measure fair value of convertible senior note | 3.70% | ||||
Conversion rate | 0.0021845 | ||||
Conversion price (in dollars per share) | $ / shares | $ 457.77 | ||||
Threshold common stock trading days | 20 | ||||
Threshold consecutive common stock trading days | 30 | ||||
Threshold percentage of common stock price trigger | 130.00% | ||||
Threshold note trading days | 5 | ||||
Threshold consecutive note trading days | 10 | ||||
Threshold percentage of note price trigger | 98.00% | ||||
Convertible stock price trigger (in dollars per share) | $ / shares | $ 595.10 | ||||
Redemption price, percentage | 100.00% | ||||
2021 | |||||
Debt Instrument [Line Items] | |||||
Stated rate | 0.50% | ||||
Principal amount of notes outstanding | $ | $ 517,000,000 | $ 517,000,000 | $ 517,000,000 | ||
Effective interest rate used to measure fair value of convertible senior note | 3.50% | ||||
Conversion rate | 0.0039318 | ||||
Conversion price (in dollars per share) | $ / shares | $ 254.34 | ||||
Threshold common stock trading days | 20 | ||||
Threshold consecutive common stock trading days | 30 | ||||
Threshold percentage of common stock price trigger | 130.00% | ||||
Threshold note trading days | 5 | ||||
Threshold consecutive note trading days | 10 | ||||
Threshold percentage of note price trigger | 98.00% | ||||
2019 | |||||
Debt Instrument [Line Items] | |||||
Stated rate | 0.00% | ||||
Principal amount of notes outstanding | $ | $ 633,000,000 | ||||
Effective interest rate used to measure fair value of convertible senior note | 2.90% | ||||
Number of shares of common stock issued upon conversion (in shares) | shares | 400,000 |
Stockholders' Equity - Narrativ
Stockholders' Equity - Narrative (Details) shares in Millions | Mar. 29, 2020shares |
2015 Stock Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares available for issuance (in shares) | 4.1 |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Restricted Stock Activity and Related Information (Details) shares in Thousands | 3 Months Ended |
Mar. 29, 2020$ / sharesshares | |
Restricted Stock Units (RSU) | |
Stock Units | |
Outstanding at period start (in shares) | shares | 1,700 |
Awarded (in shares) | shares | 82 |
Vested (in shares) | shares | (26) |
Cancelled (in shares) | shares | (70) |
Outstanding at period end (in shares) | shares | 1,686 |
Weighted-Average Grant Date Fair Value per Share | |
Outstanding at period start (in dollars per share) | $ / shares | $ 271.49 |
Awarded (in dollars per share) | $ / shares | 300.29 |
Vested (in dollars per share) | $ / shares | 198.43 |
Cancelled (in dollars per share) | $ / shares | 260.73 |
Outstanding at period end (in dollars per share) | $ / shares | $ 274.46 |
Performance Stock Units (PSU) | |
Stock Units | |
Outstanding at period start (in shares) | shares | 271 |
Awarded (in shares) | shares | 55 |
Cancelled (in shares) | shares | (30) |
Outstanding at period end (in shares) | shares | 296 |
Weighted-Average Grant Date Fair Value per Share | |
Outstanding at period start (in dollars per share) | $ / shares | $ 258.66 |
Awarded (in dollars per share) | $ / shares | 348.46 |
Cancelled (in dollars per share) | $ / shares | 254.81 |
Outstanding at period end (in dollars per share) | $ / shares | $ 275.65 |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of Stock Option Activity Under all Stock Option Plans (Details) shares in Thousands | 3 Months Ended |
Mar. 29, 2020$ / sharesshares | |
Options | |
Outstanding at period start (in shares) | shares | 58 |
Exercised (in shares) | shares | (17) |
Outstanding at period end (in shares) | shares | 41 |
Exercisable at period end (in shares) | shares | 41 |
Weighted-Average Exercise Price | |
Outstanding at period start (in dollars per share) | $ / shares | $ 56.65 |
Exercised (in dollars per share) | $ / shares | 36.62 |
Outstanding at period end (in dollars per share) | $ / shares | 64.63 |
Exercisable at period end (in dollars per share) | $ / shares | $ 64.63 |
Stockholders' Equity - Narrat_2
Stockholders' Equity - Narrative - Employee Stock Purchase Plan (Details) - ESPP - Employee Stock shares in Millions | 3 Months Ended |
Mar. 29, 2020shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Specified percentage of the fair market value of the common stock on the first or last day of the offering period whichever is lower at which stock is purchased | 85.00% |
Total shares issued under the ESPP (in shares) | 0.1 |
Shares available for issuance (in shares) | 13.4 |
Stockholders' Equity - Narrat_3
Stockholders' Equity - Narrative - Share Repurchases (Details) - USD ($) shares in Millions | 3 Months Ended | ||
Mar. 29, 2020 | Mar. 31, 2019 | Feb. 05, 2020 | |
Class of Stock [Line Items] | |||
Common stock repurchases | $ 188,000,000 | $ 63,000,000 | |
Common Stock | |||
Class of Stock [Line Items] | |||
Stock repurchase program, authorized amount | $ 750,000,000 | ||
Repurchased common stock (in shares) | 0.7 | ||
Common stock repurchases | $ 187,000,000 | ||
Dollar amount remaining in authorized stock repurchase program | $ 563,000,000 |
Stockholders' Equity - Summar_3
Stockholders' Equity - Summary of Share-based Compensation Expense for all Stock Awards (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense before taxes | $ 39 | $ 51 |
Related income tax benefits | (9) | (10) |
Share-based compensation expense, net of taxes | 30 | 41 |
Cost of product revenue | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense before taxes | 5 | 5 |
Cost of service and other revenue | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense before taxes | 1 | 1 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense before taxes | 15 | 18 |
Selling, general and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense before taxes | $ 18 | $ 27 |
Stockholders' Equity - Summar_4
Stockholders' Equity - Summary of Assumptions Used to Estimate the Weighted Average Fair Value Per Share (Details) $ / shares in Units, $ in Millions | 3 Months Ended |
Mar. 29, 2020USD ($)$ / shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost related to stock options, restricted stock, and ESPP shares granted to date | $ | $ 458 |
Weighted-average period of unrecognized compensation cost related to stock options, restricted stock, and ESPP shares granted to date | 2 years 4 months 24 days |
Employee Stock | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected volatility, minimum | 30.00% |
Expected volatility, maximum | 37.00% |
Expected dividends | 0.00% |
Weighted-average fair value per share (in dollars per share) | $ / shares | $ 77.19 |
Minimum | Employee Stock | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Risk-free interest rate | 1.46% |
Expected term | 6 months |
Maximum | Employee Stock | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Risk-free interest rate | 2.56% |
Expected term | 1 year |
Supplemental Balance Sheet De_3
Supplemental Balance Sheet Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Trade accounts receivable, gross | $ 473 | $ 575 |
Allowance for credit losses | (1) | (2) |
Total accounts receivable, net | $ 472 | $ 573 |
Supplemental Balance Sheet De_4
Supplemental Balance Sheet Details - Summary of Inventory (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Raw materials | $ 114 | $ 108 |
Work in process | 243 | 225 |
Finished goods | 27 | 26 |
Total inventory | $ 384 | $ 359 |
Supplemental Balance Sheet De_5
Supplemental Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($) $ in Millions | Mar. 29, 2020 | Dec. 29, 2019 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Contract liabilities, current portion | $ 158 | $ 167 |
Accrued compensation expenses | 112 | 154 |
Accrued taxes payable | 54 | 86 |
Operating lease liabilities, current portion | 46 | 45 |
Other, including warranties | 55 | 64 |
Total accrued liabilities | $ 425 | $ 516 |
Supplemental Balance Sheet De_6
Supplemental Balance Sheet Details - Summary of Changes in Reserve for Product Warranties (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 29, 2020 | Mar. 31, 2019 | |
Reserve for product warranties [Roll Forward] | ||
Balance at beginning of period | $ 14 | $ 19 |
Additions charged to cost of product revenue | 3 | 3 |
Repairs and replacements | (5) | (6) |
Balance at end of period | $ 12 | $ 16 |
Income Taxes (Details)
Income Taxes (Details) | 3 Months Ended |
Mar. 29, 2020 | |
Income Tax Disclosure [Abstract] | |
Effective tax rate | 2.50% |
Segment Information (Details)
Segment Information (Details) $ in Millions | 3 Months Ended | |
Mar. 29, 2020USD ($)segment | Mar. 31, 2019USD ($) | |
Segment Reporting [Abstract] | ||
Number of reportable segments | segment | 1 | |
Segment Reporting Information [Line Items] | ||
Revenue | $ 859 | $ 846 |
Income (loss) from operations | 189 | 204 |
Operating Segments | Core Illumina | ||
Segment Reporting Information [Line Items] | ||
Revenue | 859 | 846 |
Income (loss) from operations | 189 | 221 |
Operating Segments | Helix | ||
Segment Reporting Information [Line Items] | ||
Revenue | 0 | 1 |
Income (loss) from operations | 0 | (18) |
Elimination of intersegment | ||
Segment Reporting Information [Line Items] | ||
Revenue | 0 | (1) |
Income (loss) from operations | $ 0 | $ 1 |